STUDY OF THE REGULARITIES OF THE INFLUENCE OF PLATELET-RICH PLASMA IN THE COMPLEX TREATMENT OF CORNEAL ULCERS
Abstract
The cornea refers to the fibrous membrane of the eye, which is constantly exposed to environmental factors. In recent years, the attention of ophthalmologists has been attracted by the technology associated with the use of platelet-rich autoplasma (PRP) for the treatment of patients with corneal diseases. Traditional treatments for corneal ulcers include topical application of anti-inflammatory drugs containing preservatives, which can aggravate the symptoms of inflammatory diseases of the ocular surface and increase tear film instability.
The study included 129 patients with corneal ulcers. The first group of patients received traditional treatment. In the second group of patients, intrastromal administration of an antibiotic into the cornea was added to the traditional treatment. The third group of patients received complex treatment with the addition of platelet-rich plasma instillations.
The results showed that the use of platelet-rich plasma in combination with intrastromal administration of an antibiotic can increase the effectiveness of the treatment of corneal ulcers by accelerating the epithelialization time by 18.6% in relation to patients of the first group and by 11.6% in relation to patients of the second group. ... Allows to reduce the manifestations of signs of inflammation on the 10th day of treatment by 34.8% in relation to patients of the first group and by 13.9% in relation to patients of the second group. These results were combined with an increase in tear production and stability of the tear film against the background of its primary decrease, thereby preventing the development of keratopathy.
References
1. Buzard K.A. Introduction to biomechanics of the cornea. Refract Corneal Surg. 1992; 8 (2): 127-138.
2. The Eye. Davson H. (Ed.) AcademicPress; 1984. 614.
3. Маслова-Хорошилова И.П. Травматическое поражение глаз. В книге: Многотомное руководство по патологической анатомии. Т. 1. М: Медгиз; 1963: 575-589.
4. Dische Z. Biochemistry of connective tissue of the vertebrate eye. Int Rev Connect Tissue Res. 1970; 5: 209-279. doi:10.1016/b978-0-12-363705-5.50010-5
5. Hassan A.U., Hassan G., Rasool Z., Hassan S. Clinical Outcomes of Elastin Fibre Defects. J Cytol Histol. 2013; 4: 166. doi: 10.4172/2157-7099.1000166
6. Gumbiner B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996; 84: 345-357.
7. Huang R.Y., Guilford P., Thiery J.P. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci. 2012; 125 (Pt 19): 4417-4422. doi: 10.1242/jcs.099697
8. Аяутдин Р.Н., Иежица И.Н. Транспорт лекарственных средств через роговицу глаза: перспективы применения липосомальных лекарственных форм. Вестник офтальмологии. 2014; 4: 117-122.
9. Багров С.Н. Источники регенерации роговой оболочки глаза. Офтальмологический журнал 1980; 1: 231-233.
10. Arshdeep, Kumaran M.S. Platelet-rich plasma in dermatology: boon or a bane?. Indian J Dermatol Venereol Leprol. 2014; 80 (1): 5-14. doi: 10.4103/0378-6323.125467
11. Ачкасов Е.Е., Безуглов Э.Н., Ульянов А.А. и соавт. Применение аутоплазмы, обогащенной тромбоцитами, в клинической практике. Биомедицина. 2013; 4: 46-59.
12. Ахмеров Р., Зарудий Р., Рычкова И. с соавт. Плазмолифтинг (Plasmolifting).- Лечение возрастной атрофии кожи богатой тромбоцитами аутоплазмой. Эстетическая медицина. 2011; 2: 181-187.
13. Dragonas P., Katsaros T., Avila-Ortiz G., Chambrone L., Schiavo J.H., Palaiologou A. Effects of leukocyte-platelet-rich fibrin (L-PRF) in different intraoral bone grafting procedures: a systematic review. Int J Oral Maxillofac Surg. 2019; 48 (2): 250-262. doi: 10.1016/j.ijom.2018.06.003
14. Somabhai K.R., Dhanjibhai P.N., Sinha M. A clinical microbiological study of corneal ulcer patients at western Gujarat, India. Acta Med Iran. 2013; 51 (6): 399-403.
15. Park J.B., Matsuura M., Han K.Y. et al. Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor. J Periodontol. 1995; 66 (6): 462-477. doi: 10.1902/jop.1995.66.6.462
16. Giannobile W.V. Periodontal tissue engineering by growth factors. Bone. 1996; 19 (1 Suppl): 23S-37S. doi: 10.1016/s8756-3282(96)00127-5
17. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science. 2002; 296 (5573): 1646-1647. doi:10.1126/science.1071809
18. Wang J-Y, Xie L-X, Song X-S, Zhao J. Trends in the indications for penetrating keratoplasty in Shandong, 2005-2010. Int J Ophthalmol. 2011; 4 (5): 492-497.
19. Oladigbolu K., Rafindadi A., Abah E., Samaila E. Corneal ulcers in a tertiary hospital in Northern Nigeria. Ann Afr Med. 2013; 12 (3): 165-170. doi:10.4103/1596-3519.117626
20. Panda A., Satpathy G., Nayak N., Kumar S., Kumar A. Demographic pattern, predisposing factors and management of ulcerative keratitis: evaluation of one thousand unilateral cases at a tertiary care centre. Clin Exp Ophthalmol. 2007; 35 (1): 44-50. doi:10.1111/j.1442-9071.2007.01417.x
21. Suárez-Barrio C., Etxebarria J., Hernáez-Moya R. et al. Hyaluronic Acid Combined with Serum Rich in Growth Factors in Corneal Epithelial Defects. Int J Mol Sci. 2019; 20 (7): 1655. doi: 10.3390/ijms20071655
22. Dohan Ehrenfest D.M., Bielecki T., Del Corso M., Inchingolo F., Sammartino G. Shedding light in the controversial terminology for platelet-rich products: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet-leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. J Biomed Mater Res A. 2010; 95 (4): 1280-1282. doi: 10.1002/jbm.a.32894
23. He L., Lin Y., Hu X., Zhang Y., Wu H. A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 108 (5): 707-713. doi: 10.1016/j.tripleo.2009.06.044
24. Dohan Ehrenfest D.M., Rasmusson L., Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009; 27 (3): 158-167. doi: 10.1016/j.tibtech.2008.11.009
25. Дрожжина Г. И., Тройченко Л. Ф., Драгомирецкая Е. И. Эффективность применения аутосыворотки крови в компексном консервативном лечении персистирующих эпителиальных дефектов и торпидных язв роговицы постинфекционнойи нейропаралитческой этиологии. Офтальмологический журнал. 2012; 5: 6-12.
26. Yamada C., King K.E., Ness P.M. Autologous serum eyedrops: literature review and implications for transfusion medicine specialists. Transfusion. 2008; 48 (6): 1245-1255. doi: 10.1111/j.1537-2995.2008.01665.x
27. Lambiase A., Rama P., Bonini S., Caprioglio G., Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998; 338 (17): 1174-1180. doi: 10.1056/NEJM199804233381702
28. López-Plandolit S., Morales M.C., Freire V., Etxebarría J., Durán J.A. Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea. 2010; 29 (8): 843-848. doi: 10.1097/ICO.0b013e3181a81820
29. Quinto G.G., Campos M., Behrens A. Autologous serum for ocular surface diseases. Arq Bras Oftalmol. 2008; 71 (6 Suppl): 47-54.
30. Kojima T., Higuchi A., Goto E., Matsumoto Y., Dogru M., Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008; 27 (Suppl 1): S25-S30. doi: 10.1097/ICO.0b013e31817f3a0e
31. Noble B.A., Loh R.S., MacLennan S. et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004; 88 (5): 647-652. doi: 10.1136/bjo.2003.026211
32. Lagnado R., King A.J., Donald F., Dua H.S. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol. 2004; 88 (4): 464-465. doi: 10.1136/bjo.2003.025528
33. Matsumoto Y., Dogru M., Goto E. et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004; 111 (6): 1115-1120. doi: 10.1016/j.ophtha.2003.10.019
34. Akyol-Salman I. Effects of autologous serum eye drops on corneal wound healing after superficial keratectomy in rabbits. Cornea. 2006; 25 (10): 1178-1181. doi: 10.1097/01.ico.0000208817.40237.8c
35. Лебедев О.И., Калижникова Е.А., Яворский А.Е. Механизмы и результаты действия бензалкония хлорида на ткани глаза. РМЖ. Клиническая офтальмология. 2013; 14 (2): 63-66.
36. Pisella P.J., Debbasch C., Hamard P. et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004; 45 (5): 1360-1368. doi: 10.1167/iovs.03-1067
37. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J. 1997; 326 (Pt 1): 1-16. doi: 10.1042/bj3260001
38. Li J., Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. Role of the Na(+)/H(+)-antiport. J Biol Chem. 1995; 270 (7): 3203-3211. doi: 10.1074/jbc.270.7.3203
39. Geerling G., Maclennan S., Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004; 88 (11): 1467-1474. doi: 10.1136/bjo.2004.044347
40. Ситник Г.В.. Современные подходы к лечению язв роговицы. Медицинский журнал. 2007; 4: 100-104.
2. The Eye. Davson H. (Ed.) AcademicPress; 1984. 614.
3. Маслова-Хорошилова И.П. Травматическое поражение глаз. В книге: Многотомное руководство по патологической анатомии. Т. 1. М: Медгиз; 1963: 575-589.
4. Dische Z. Biochemistry of connective tissue of the vertebrate eye. Int Rev Connect Tissue Res. 1970; 5: 209-279. doi:10.1016/b978-0-12-363705-5.50010-5
5. Hassan A.U., Hassan G., Rasool Z., Hassan S. Clinical Outcomes of Elastin Fibre Defects. J Cytol Histol. 2013; 4: 166. doi: 10.4172/2157-7099.1000166
6. Gumbiner B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996; 84: 345-357.
7. Huang R.Y., Guilford P., Thiery J.P. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci. 2012; 125 (Pt 19): 4417-4422. doi: 10.1242/jcs.099697
8. Аяутдин Р.Н., Иежица И.Н. Транспорт лекарственных средств через роговицу глаза: перспективы применения липосомальных лекарственных форм. Вестник офтальмологии. 2014; 4: 117-122.
9. Багров С.Н. Источники регенерации роговой оболочки глаза. Офтальмологический журнал 1980; 1: 231-233.
10. Arshdeep, Kumaran M.S. Platelet-rich plasma in dermatology: boon or a bane?. Indian J Dermatol Venereol Leprol. 2014; 80 (1): 5-14. doi: 10.4103/0378-6323.125467
11. Ачкасов Е.Е., Безуглов Э.Н., Ульянов А.А. и соавт. Применение аутоплазмы, обогащенной тромбоцитами, в клинической практике. Биомедицина. 2013; 4: 46-59.
12. Ахмеров Р., Зарудий Р., Рычкова И. с соавт. Плазмолифтинг (Plasmolifting).- Лечение возрастной атрофии кожи богатой тромбоцитами аутоплазмой. Эстетическая медицина. 2011; 2: 181-187.
13. Dragonas P., Katsaros T., Avila-Ortiz G., Chambrone L., Schiavo J.H., Palaiologou A. Effects of leukocyte-platelet-rich fibrin (L-PRF) in different intraoral bone grafting procedures: a systematic review. Int J Oral Maxillofac Surg. 2019; 48 (2): 250-262. doi: 10.1016/j.ijom.2018.06.003
14. Somabhai K.R., Dhanjibhai P.N., Sinha M. A clinical microbiological study of corneal ulcer patients at western Gujarat, India. Acta Med Iran. 2013; 51 (6): 399-403.
15. Park J.B., Matsuura M., Han K.Y. et al. Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor. J Periodontol. 1995; 66 (6): 462-477. doi: 10.1902/jop.1995.66.6.462
16. Giannobile W.V. Periodontal tissue engineering by growth factors. Bone. 1996; 19 (1 Suppl): 23S-37S. doi: 10.1016/s8756-3282(96)00127-5
17. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science. 2002; 296 (5573): 1646-1647. doi:10.1126/science.1071809
18. Wang J-Y, Xie L-X, Song X-S, Zhao J. Trends in the indications for penetrating keratoplasty in Shandong, 2005-2010. Int J Ophthalmol. 2011; 4 (5): 492-497.
19. Oladigbolu K., Rafindadi A., Abah E., Samaila E. Corneal ulcers in a tertiary hospital in Northern Nigeria. Ann Afr Med. 2013; 12 (3): 165-170. doi:10.4103/1596-3519.117626
20. Panda A., Satpathy G., Nayak N., Kumar S., Kumar A. Demographic pattern, predisposing factors and management of ulcerative keratitis: evaluation of one thousand unilateral cases at a tertiary care centre. Clin Exp Ophthalmol. 2007; 35 (1): 44-50. doi:10.1111/j.1442-9071.2007.01417.x
21. Suárez-Barrio C., Etxebarria J., Hernáez-Moya R. et al. Hyaluronic Acid Combined with Serum Rich in Growth Factors in Corneal Epithelial Defects. Int J Mol Sci. 2019; 20 (7): 1655. doi: 10.3390/ijms20071655
22. Dohan Ehrenfest D.M., Bielecki T., Del Corso M., Inchingolo F., Sammartino G. Shedding light in the controversial terminology for platelet-rich products: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet-leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. J Biomed Mater Res A. 2010; 95 (4): 1280-1282. doi: 10.1002/jbm.a.32894
23. He L., Lin Y., Hu X., Zhang Y., Wu H. A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 108 (5): 707-713. doi: 10.1016/j.tripleo.2009.06.044
24. Dohan Ehrenfest D.M., Rasmusson L., Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009; 27 (3): 158-167. doi: 10.1016/j.tibtech.2008.11.009
25. Дрожжина Г. И., Тройченко Л. Ф., Драгомирецкая Е. И. Эффективность применения аутосыворотки крови в компексном консервативном лечении персистирующих эпителиальных дефектов и торпидных язв роговицы постинфекционнойи нейропаралитческой этиологии. Офтальмологический журнал. 2012; 5: 6-12.
26. Yamada C., King K.E., Ness P.M. Autologous serum eyedrops: literature review and implications for transfusion medicine specialists. Transfusion. 2008; 48 (6): 1245-1255. doi: 10.1111/j.1537-2995.2008.01665.x
27. Lambiase A., Rama P., Bonini S., Caprioglio G., Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998; 338 (17): 1174-1180. doi: 10.1056/NEJM199804233381702
28. López-Plandolit S., Morales M.C., Freire V., Etxebarría J., Durán J.A. Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea. 2010; 29 (8): 843-848. doi: 10.1097/ICO.0b013e3181a81820
29. Quinto G.G., Campos M., Behrens A. Autologous serum for ocular surface diseases. Arq Bras Oftalmol. 2008; 71 (6 Suppl): 47-54.
30. Kojima T., Higuchi A., Goto E., Matsumoto Y., Dogru M., Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008; 27 (Suppl 1): S25-S30. doi: 10.1097/ICO.0b013e31817f3a0e
31. Noble B.A., Loh R.S., MacLennan S. et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004; 88 (5): 647-652. doi: 10.1136/bjo.2003.026211
32. Lagnado R., King A.J., Donald F., Dua H.S. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol. 2004; 88 (4): 464-465. doi: 10.1136/bjo.2003.025528
33. Matsumoto Y., Dogru M., Goto E. et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004; 111 (6): 1115-1120. doi: 10.1016/j.ophtha.2003.10.019
34. Akyol-Salman I. Effects of autologous serum eye drops on corneal wound healing after superficial keratectomy in rabbits. Cornea. 2006; 25 (10): 1178-1181. doi: 10.1097/01.ico.0000208817.40237.8c
35. Лебедев О.И., Калижникова Е.А., Яворский А.Е. Механизмы и результаты действия бензалкония хлорида на ткани глаза. РМЖ. Клиническая офтальмология. 2013; 14 (2): 63-66.
36. Pisella P.J., Debbasch C., Hamard P. et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004; 45 (5): 1360-1368. doi: 10.1167/iovs.03-1067
37. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J. 1997; 326 (Pt 1): 1-16. doi: 10.1042/bj3260001
38. Li J., Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. Role of the Na(+)/H(+)-antiport. J Biol Chem. 1995; 270 (7): 3203-3211. doi: 10.1074/jbc.270.7.3203
39. Geerling G., Maclennan S., Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004; 88 (11): 1467-1474. doi: 10.1136/bjo.2004.044347
40. Ситник Г.В.. Современные подходы к лечению язв роговицы. Медицинский журнал. 2007; 4: 100-104.
Published
2021-12-20
How to Cite
МИХАЛЬЧЕНКО, Е. А..
STUDY OF THE REGULARITIES OF THE INFLUENCE OF PLATELET-RICH PLASMA IN THE COMPLEX TREATMENT OF CORNEAL ULCERS.
University Clinic, [S.l.], n. 4(41), p. 59-67, dec. 2021.
ISSN 1819-0464. Available at: <http://journal.dnmu.ru/index.php/UC/article/view/754>. Date accessed: 06 july 2024.
doi: https://doi.org/10.26435/uc.v0i4(41).754.
Section
Оригинальные исследования
